The White House drug policy advisor that Donald Trump has chosen to lead the White House did not endorse a proposal to change cannabis’ classification from Schedule I to Schedule III under the Controlled Substances Act.
This abstention is due in part to her new position, which prevents her publicly from supporting a similar reform.
Sara Carter is Trump’s choice to lead the White House Office of National Drug Control Policy. She called the rescheduling of cannabis a bipartisan issue, but she said that the administration needs to evaluate more data as it explores the options. She made her comments during the confirmation hearing of the U.S. Senate Judiciary Committee, which took place on September 17.
Booker asked Carter, who is legally known as Sara Bailey and whose full name is Sara Carter, what advice she could give to Trump should she get confirmed on Joe Biden’s proposal for rescheduling.
Carter noted that this is a “bipartisan” issue. He said, “I look forward to working alongside you as well all Republicans in the committee as the other Democrats.” As director, if confirmed, I would comply with federal law and perform all statutory responsibilities. We will, however, continue working extensively on research and data. “We will explore every option and continue doing that.”
She made her comments more than five week after Trump stated at a press conference on August 11 that the Schedule III would be decided by his administration “in the coming weeks.” Former Attorney General Merrick Gault signed the proposed rule after Biden’s Department of Health and Human Services had conducted a review and recommended it.
Carter said to Booker on Wednesday at Booker’s confirmation hearing, that she spoke with U.S. Department of Veterans Affairs secretary Doug Collins about the issue. This indicated that no decision had been made.
“We are all talking about the data and research we will deliver, and we’ll continue to evaluate based upon that information,” said Ms. She. I think this is very important.
Carter, who has previously expressed her support for the medical use of cannabis, had to be careful as a nominee to the ONDCP Director position.
Federal You can restrict yourself to certain areas. Under the current control status, the executive branch is prohibited from approving the U.S. Food and Drug Administration’s approval of Schedule I substances before the ONDCP. The restrictions also prevent the ONDCP to finance or sponsor research on medical cannabis or adult use cannabis.
The U.S. has not accepted cannabis as a medical drug. It is classified in Schedule I, along with heroin, LSD, and ecstasy.
Other words, Carter would be restricted in her ability to speak freely about legalizing marijuana under federal law if she were confirmed as Trump’s top drug advisor.
Booker admitted these restrictions in his confirmation hearing this week.
Booker: “It makes studying Schedule I drugs including cannabis really difficult.” Booker said, “I’m hopeful that as we work across the aisle to create legislation that allows the ONDCP study the effects that you might support this.”
Carter responded, “Absolutely.” We will keep studying the impact of this.”
Booker’s reference to the legislation is that of Evidence-Based Drug Policy Act 2025 Dina Titus (D-Nev.) and Ilhan Oma, D. Minn.), U.S. House Representatives, presented in April. The Act would give the ONDCP’s director freedom to discuss cannabis reform and research on Schedule I substances.
Titus Omar are the Democratic cochairs of the Congressional Cannabis Caucus. They introduced this act following a National Academies in 2024. You can also read about the study of The ONDCP was asked to conduct a study on the impact of cannabis legalization. It was at a time when 24 states legalized marijuana for adult use by those over 21. Forty states also legalized medical cannabis.
Titus, in an article published on April 9, said that “statutory restrictions” and the mandate to fight any efforts to reschedule substances such as cannabis are absurd. Press release. It is time to update laws to reflect cannabis’ current medical use in the United States. It’s time for the federal government to catch up with states.”
Booker, as well as other Senate Judiciary Committee Members, could submit questions to the record for Carter before Carter is confirmed. It’s not likely that she will provide any further information without an announcement from Trump’s administration regarding the Schedule III proposal.
Carter, for example, said that she would “comply” with federal laws as well as fulfill her statutory responsibilities. This is similar to what Terry Cole (DEA Administrator) stated during his tenure. confirmation hearing in April And his answers to follow up questions.
Cole said, “I will look at all the facts and circumstances individually and I’ll follow the law as well as any policy of the Department.” WriterBooker responded to one of his QFRs regarding cannabis redistribution.
Carter, a former Fox News reporter who investigated drug cartels and covered the fentanyl crisis as well as opioid crisis in November 2023, said that she may have limited access to what she could say. podcast She doesn’t “have a problem” with the legalization and monitoring of cannabis, despite her own personal views.
Carter, in a podcast, said, “I might have some issues about how I feel, but I believe cannabis is great for treating, and especially cancer patients and others with illnesses. It’s a wonderful way to deal with illness, and also the side-effects of medication, and these illnesses.” ‘So, I’m not saying we’ve got to make it illegal.”
Booker referred to Carter’s comments from the 2023 podcast during Carter’s confirmation hearing last week.
Booker noted that “you supported the use cannabis as a medical treatment, and here we have had hearings with bipartisan military personnel who spoke of the positive impact on their PTSD that it had.” I just think that now we are in a period where forty states have legalized cannabis for medical use. Unfortunately, the federal law lags behind state laws and popular opinion across all political spectrum.
Donald Trump’s nominee to serve as the White House’s top drug adviser has refrained from endorsing the proposed rule that would reclassify marijuana from Schedule I drug to Schedule III in the Controlled Substances Act.
This abstention is due in part to her new position, which prevents her publicly from supporting a similar reform.
Sara Carter is Trump’s choice to lead the White House Office of National Drug Control Policy. She called the rescheduling of cannabis a bipartisan issue, but she said that the administration needs to evaluate more research data as it explores every option. She made her comments during the confirmation hearing of the U.S. Senate Judiciary Committee, which took place on September 17.
Booker asked Carter (whose real name is Sara Bailey) how, should Carter be confirmed, she would counsel Trump regarding the rescheduling plan of Joe Biden’s era.
Carter stated, “This is an issue that crosses party lines. I am looking forward to working together with all of you and the Republicans on this committee as well as other Democrats.” If confirmed as Director, I would comply with federal law and perform all statutory responsibilities for the ONDCP. We will, however, continue working extensively on research and data. “We will explore every option and continue doing that.”
She made her comments more than five week after Trump stated at a press conference on August 11 that the Schedule III would be decided by his administration “in the coming weeks.” Merrick Garland, former attorney general, signed off the proposal rule following a recommendation from Biden’s Department of Health and Human Services.
Carter said to Booker on Wednesday at Booker’s confirmation hearing, that she spoke with U.S. Department of Veterans Affairs secretary Doug Collins about the issue. This indicated that no decision had been made.
“We are all talking about the data and research we will deliver, and we will assess based upon that information and research,” she added. I think this is very important.
Carter, who has previously expressed her support for the medical use of cannabis, had to be careful as the ONDCP Director nominee.
Federal You can restrict yourself to certain areas. The executive branch has restrictions that prevent the ONDCP supporting legalization before the U.S. Food and Drug Administration approves. The restrictions prohibit the ONDCP, under the current status of control, from funding or sponsoring any research relating to adult or medical use cannabis.
The U.S. has not accepted cannabis as a medical drug. It is classified in Schedule I, along with heroin, LSD, and ecstasy.
Other words, Carter would be restricted in her ability to speak freely about legalizing marijuana under federal law if she were confirmed as Trump’s top drug advisor.
Booker admitted these restrictions in his confirmation hearing this week.
Booker stated, “It is unfortunate that this makes it difficult to study Schedule I drugs like cannabis.” Booker said, “I’m hopeful that as we work across the aisle to create legislation that allows the ONDCP study the effects that you might support this.”
Carter replied, “Absolutely.” We will keep studying the impact of this.”
Booker’s reference to the legislation is that of Evidence-Based Drug Policy Act 2025 Dina Titus (D-Nev.) and Ilhan Oma, D. Minn.), U.S. House Representatives, presented in April. The Act would give the ONDCP’s director freedom to discuss cannabis reform while supporting research on Schedule I drugs.
Titus Omar are the Democratic cochairs of the Congressional Cannabis Caucus. They introduced this act following a National Academies in 2024. You can also read about the study of The ONDCP was asked to conduct a study on the impact of legalizing marijuana. It was at a time when 24 states legalized marijuana for adult use by those over 21. Forty states also legalized medical marijuana.
In an April article, Titus stated that “Statutory limitations on what is allowed to be studied as well as a mandate opposing any attempt to reschedule drugs like cannabis makes no sense.” Press release. “It is time to update our laws to reflect cannabis’ use in America and the medical benefits it offers. “The federal government must catch up with the states.”
Booker, as well as other Senate Judiciary Committee Members, could submit questions to the record for Carter before her confirmation. It’s not likely that she will provide any further information without an announcement from the Trump administration regarding the Schedule III proposal.
Carter, for example, said that she would “comply” with federal laws as well as fulfill her statutory responsibilities. This is similar to what Terry Cole (DEA Administrator) stated during his tenure. confirmation hearing in April And his answers to follow up questions.
Cole said, “I will look at all the facts and circumstances individually and I’ll follow the law as well as any policy of the Department.” WriterBooker, in response to a QFR he issued on cannabis rescheduling.
Carter, a former Fox News reporter who investigated drug cartels and covered the fentanyl crisis as well as opioids in November 2023 said that she may have limited access to what she could say. podcast She doesn’t “have a problem” with the legalization and monitoring of cannabis, despite her own personal views.
Carter, in a podcast, said, “I might have some issues about how I feel, but I believe cannabis is great for treating, and especially cancer patients and others with illnesses. It’s a wonderful way to deal with illness, and also the side-effects of medication, and these illnesses.” ‘So, I’m not saying we’ve got to make it illegal.”
Booker brought Carter’s comments from the 2023 podcast up during Carter’s confirmation hearing last week.
Booker stated, “You supported cannabis use for medical reasons and there were bipartisan hearings held here where military personnel spoke about how it has transformed their PTSD.” I just think that now we are in a period where forty states have legalized cannabis for medical use. Unfortunately, the federal law lags behind state laws and popular opinion across all political spectrums.
Cannabis Law Resources for Poland
Discover essential legal information about the cultivation of cannabis, its sale, and regulations governing medical products in Poland. These guides will help you understand the legal requirements, such as certifications and permissions.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland